Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

Jonathan D. Edgeworth, Domenico Merante, Sanjay Patel, Christopher Young, Paul Jones, Seema Vithlani, Duncan Wyncoll, Peter Roberts, Andrew Jones, Tsutae Den Nagata, Mari Ariyasu, David M. Livermore, Richard Beale

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Abstract

Serious infections such as endocarditis due to extremely drug-resistance gram-negative bacteria are an increasing challenge. Here, we present successful adjunctive use of cefiderocol for a patient with persistently bacteremic healthcare-associated native aortic valve endocarditis due to an extended-spectrum beta-lactamase-positive Pseudomonas aeruginosa susceptible in vitro only to colistin, following failure of conventional therapeutic options.

Original languageEnglish
Pages (from-to)1932-1934
Number of pages3
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume68
Issue number11
DOIs
Publication statusPublished - 12 Dec 2018

Keywords

  • Pseudomonas aeruginosa
  • cefiderocol
  • drug resistance
  • endocarditis
  • microbial

Fingerprint

Dive into the research topics of 'Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this